Compare Cassava Sciences Inc (FLNA) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Snap Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Snap Inc trades at $5.51 (market cap $9.05B). The key difference: Snap Inc is far larger — about 189.5× Cassava Sciences Inc's market cap, and Snap Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SNAP | |
|---|---|---|
Market Cap | $47.75M | $9.05B |
Sector | Health | Media |
52-Week High | $4.64 | $9.09 |
52-Week Low | $0.87 | $3.93 |
Enterprise Value | -$34.93M | $10.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
